Incyte Corp
NASDAQ:INCY
Incyte Corp
Other Current Assets
Incyte Corp
Other Current Assets Peer Comparison
Competitive Other Current Assets Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Incyte Corp
NASDAQ:INCY
|
Other Current Assets
$189.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
21%
|
CAGR 10-Years
29%
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$4.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$2.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$511.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$414.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Incyte Corp's Other Current Assets?
Other Current Assets
189.2m
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Other Current Assets amounts to 189.2m USD.
What is Incyte Corp's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
29%
Over the last year, the Other Current Assets growth was -3%. The average annual Other Current Assets growth rates for Incyte Corp have been 37% over the past three years , 21% over the past five years , and 29% over the past ten years .